Challenges and opportunities in NASH drug development
SA Harrison, AM Allen, J Dubourg, M Noureddin… - Nature medicine, 2023 - nature.com
Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic
steatohepatitis (NASH), represent a growing worldwide epidemic and a high unmet medical …
steatohepatitis (NASH), represent a growing worldwide epidemic and a high unmet medical …
[HTML][HTML] Changing epidemiology, global trends and implications for outcomes of NAFLD
Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common liver
disease globally and is currently estimated to affect 38% of the global population. Only a …
disease globally and is currently estimated to affect 38% of the global population. Only a …
A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
SA Harrison, P Bedossa, CD Guy… - … England Journal of …, 2024 - Mass Medical Soc
Background Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no
approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta …
approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta …
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Abbreviations: AASLD, American Association for the Study of Liver Diseases; AI, artificial
intelligence; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC …
intelligence; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC …
Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH
Background Pegozafermin is a long-acting glycopegylated (pegylated with the use of site-
specific glycosyltransferases) fibroblast growth factor 21 (FGF21) analogue in development …
specific glycosyltransferases) fibroblast growth factor 21 (FGF21) analogue in development …
Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease–novel insights into cellular communication circuits
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease and is
emerging as the leading cause of cirrhosis, liver transplantation and hepatocellular …
emerging as the leading cause of cirrhosis, liver transplantation and hepatocellular …
[HTML][HTML] Prospective study of outcomes in adults with nonalcoholic fatty liver disease
Background The prognoses with respect to mortality and hepatic and nonhepatic outcomes
across the histologic spectrum of nonalcoholic fatty liver disease (NAFLD) are not well …
across the histologic spectrum of nonalcoholic fatty liver disease (NAFLD) are not well …
[HTML][HTML] A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH
SM Francque, P Bedossa, V Ratziu… - … England Journal of …, 2021 - Mass Medical Soc
Background Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need.
Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that …
Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that …
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis–2021 update
Non-invasive tests are increasingly being used to improve the diagnosis and
prognostication of chronic liver diseases across aetiologies. Herein, we provide the latest …
prognostication of chronic liver diseases across aetiologies. Herein, we provide the latest …
Lifestyle interventions in nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) is a dynamic chronic liver disease that develops in
close association with metabolic irregularities. Between 2016 and 2019, the global …
close association with metabolic irregularities. Between 2016 and 2019, the global …